Skip to main content

The state of drug pricing in 2022

Drug pricing reform in the U.S. is both further along than it's been in years and stuck facing the same long odds that have frustrated past attempts at a major federal overhaul. If recent actions from Congress and the White House are any indication, pricing looks set to remain pharma's greatest reputational risk of 2022 and beyond.

included in this trendline
  • Senate passage of drug pricing bill brings major defeat closer for pharma industry
  • With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
  • Can biosimilars, after years of limited impact, finally make a mark in the US?
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.